PX'Therapeutics–CEA: PSAQ technology, 201009 license excl existent to Promise Advanced Proteomics from CEA

	Period	2010-09-14
	Partner, 1st	Promise Advanced Proteomics
	Group	PX’Therapeutics (Group)
	Partner, 2nd	CEA Industrie
	Group	CEA Industrie (Group)
	Product	PSAQ™ method (Protein Standard for Absolute Quantification)
	Product 2	mass spectrometry services (MS services)
	Index term 2	PX'Therapeutics–CEA: investment, 20109 existent CEA is minority shareholder of Promise Advanced Proteomics

Promise Advanced Proteomics. (9/14/10). "Corporate Information by E-Mail".

A spokesperson for Promise Advanced Proteomics responded to [iito] Business Intelligence that Promise is a 51% subsidiary of PX'Therapeutics. Promise licensed its patented PSAQ method from CEA, which also holds an interest in the company.

Promise Advanced Proteomics uses a QTrap4000 (AB SCIEX) to analyse biologcial samples containing the PSAQ standard. For quality control of the PSAQ an Orbitrap (Thermo Scientific) is used. Routinely this is an OrbiTrap XL, but the company also has an OrbiTrap Discovery. The QTrap4000 is also used to control the incorporation of labelled amino acids.

Record changed: 2011-11-25

Follow Us!

Top News

Upcoming Events

Associations

Partners

PX'Therapeutics–CEA: PSAQ technology, 201009 license excl existent to Promise Advanced Proteomics from CEA

Promise Advanced Proteomics. (9/14/10). "Corporate Information by E-Mail".

More documents for PX’Therapeutics (Group)